BI
SNDX icon

BVF Inc’s Syndax Pharmaceuticals SNDX Stock Holding History

BVF Inc’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,875,000
Closed -$44.6M – 66
2024
Q1 		$44.6M Hold
1,875,000
– – 1.23% 24
2023
Q4 		$40.5M Buy
+1,875,000
New +$28.8M 1.01% 26
2023
Q2 		– Sell
-2,143,197
Closed -$45.3M – 72
2023
Q1 		$45.3M Buy
2,143,197
+692,000
+48% +$17.2M 1.65% 19
2022
Q4 		$36.9M Sell
1,451,197
-346,888
-19% -$8.09M 1.56% 25
2022
Q3 		$43.2M Sell
1,798,085
-558,849
-24% -$12.5M 1.78% 20
2022
Q2 		$45.3M Sell
2,356,934
-37,780
-2% -$629K 2.19% 17
2022
Q1 		$41.6M Buy
2,394,714
+295,000
+14% +$4.97M 1.66% 21
2021
Q4 		$46M Sell
2,099,714
-386,715
-16% -$7.15M 1.67% 18
2021
Q3 		$47.5M Hold
2,486,429
– – 1.85% 16
2021
Q2 		$42.7M Buy
2,486,429
+2,322,905
+1,421% +$42.5M 1.6% 16
2021
Q1 		$3.66M Sell
163,524
-715,000
-81% -$16.2M 0.14% 63
2020
Q4 		$19.5M Sell
878,524
-1,592,154
-64% -$33M 0.77% 34
2020
Q3 		$36.5M Hold
2,470,678
– – 1.99% 22
2020
Q2 		$36.6M Buy
2,470,678
+330,894
+15% +$5.04M 2.26% 18
2020
Q1 		$23.5M Buy
2,139,784
+375,000
+21% +$3.52M 2.19% 16
2019
Q4 		$15.5M Hold
1,764,784
– – 1.17% 21
2019
Q3 		$13.2M Hold
1,764,784
– – 1.39% 24
2019
Q2 		$16.4M Sell
1,764,784
-222,885
-11% -$1.62M 1.79% 20
2019
Q1 		$10.4M Hold
1,987,669
– – 1.17% 27
2018
Q4 		$8.85M Buy
1,987,669
+754,051
+61% +$4.13M 1.16% 28
2018
Q3 		$9.97M Hold
1,233,618
– – 0.88% 36
2018
Q2 		$8.66M Sell
1,233,618
-2,000,000
-62% -$19.6M 0.85% 33
2018
Q1 		$46M Hold
3,233,618
– – 4.66% 6
2017
Q4 		$28.3M Buy
+3,233,618
New +$32M 3.41% 9

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BVF Inc's SNDX Position: Q2 2024 in Review

BVF Inc sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 1,875,000 shares — an estimated $44.6M sold.

BVF Inc first reported a position in SNDX in Q4 2017 and held it in 24 quarters. The position peaked at $47.5M in Q3 2021. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

  • BVF Inc reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • BVF Inc sold 1,875,000 Syndax Pharmaceuticals shares in Q2 2024, an estimated $44.6M.
  • BVF Inc first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 24 quarters.
  • BVF Inc's Syndax Pharmaceuticals position peaked at $47.5M in Q3 2021.
  • 196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on BVF Inc's 13F filing for Q2 2024, filed 14 Aug 2024.